NRAS and melanoma: Acral melanoma typically has a lower mutation burden and lower rates of B-RAF proto-oncogene (BRAF) and neuroblastoma RAS viral oncogene homolog (NRAS) mutations as compared to its non-acral melanoma counterparts.